Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 8, 2004, Pages 3841-3846

  Smith, Matthew R ^a   Fallon, Mary Anne ^a   Lee, Hang ^a   Finkelstein, Joel S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; RALOXIFENE;

ADULT; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR; HUMAN; HYPOGONADISM; LUMBAR SPINE; LUNG EMBOLISM; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DOUBLE-BLIND METHOD; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSTATIC NEOPLASMS; PULMONARY EMBOLISM; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TESTOSTERONE;

EID: 4043134370     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-032058     Document Type: Article

References (28)

1. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C 1999 Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol 161:1219-1222
2. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS 2001 Pamidronate to prevent bone loss in men receiving gonadotropin releasing hormone agonist therapy for prostate cancer. N Engl J Med 345:948-955
3. Eriksson S, Eriksson A, Stege R, Carlstrom K 1995 Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57:97-99
4. Diamond T, Campbell J, Bryant C, Lynch W 1998 The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561-1566
5. Daniell HW 1997 Osteoporosis after orchiectomy for prostate cancer. J Urol 157:439-444
6. Townsend MF, Sanders WH, Northway RO, Graham Jr SD 1997 Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79:545-550
7. Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K 2000 Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int 86:449-452
8. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resniek M 2001 Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol 166:1724-1728
9. Need AG, Horowitz M, Stiliano A, Scopacasa F, Morris HA, Chatterton BE 1996 Vitamin D receptor genotypes are related to bone size and bone density in men. Eur J Clin Invest 26:793-796
10. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL 1988 Evidence of estrogen receptors in normal human osteoblast-like cells. Science 241:84-86
11. Oursler MJ, Pederson L, Fitzpatrick L, Riggs BL, Spelsberg T 1994 Human giant cell tumors of the bone (osteoclastomas) are estrogen target cells. Proc Natl Acad Sci USA 91:5227-5231
12. Slemenda CW, Longcope C, Zhou L, Hui SL, Peacock M, Johnston CC 1997 Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens. J Clin Invest 100:1755-1759
13. Khosla S, Melton 3rd LJ Atkinson EJ, O'Fallon WM, Klee GG, Riggs BL 1998 Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 83:2266-2274
14. Greendale GA, Edelstein S, Barrett-Connor E 1997 Endogenous sex steroids and bone mineral density in older women and men: the Rancho Bernardo Study. J Bone Miner Res 12:1833-1843
15. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S 2000 Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest 106:1553-1560
16. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS 2003 Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab 88:204-210
17. Balfour JA, Goa KL 1998 Raloxifene. Drugs Aging 12:335-341; discussion 342
18. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647
19. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
20. Rosner B 1990 Fundamentals of biostatistics. 3rd ed. Boston: PWS-Kent Publishing Company
21. Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C 1996 A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 11:835-842
22. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J 2004 Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351
23. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, Carbone PP, DeMets DL 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856
24. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S 1996 Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 14:78-84
25. Doran PM, Riggs BL, Atkinson EJ, Khosla S 2001 Effects of raloxifene, a selective estrogen receptor modulator, on bone turnover markers and serum sex steroid and lipid levels in elderly men. J Bone Miner Res 16:2118-2125
26. Smith MR, Fallon MA, Goode MJ 2003 Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer. Urology 61:127-131
27. Diamond TH, Winters J, Smith A, De Souza P, Kersley JH, Lynch WJ, Bryant C 2001 The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study. Cancer 92:1444-1450
28. Smith MR, Eastham J, Gleason D, Shasha D, Tchekmedyian S, Zinner N 2003 Randomized controlled trial of zoledronic acid to prevent bone loss in men undergoing androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169:2008-2012